[HTML][HTML] Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study

K Kabashima, M Furue, JM Hanifin, G Pulka… - Journal of Allergy and …, 2018 - Elsevier
Background Nemolizumab, an anti–IL-31 receptor A mAb, improved pruritus, dermatitis, and
sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled
by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled
study (part A; NCT01986933). Objective We sought to assess the long-term efficacy and
safety of nemolizumab injected subcutaneously every 4 weeks (Q4W) or every 8 weeks
(Q8W) in a 52-week, double-blind extension (part B). Methods During part B, patients …